155 related articles for article (PubMed ID: 38229093)
1. Evaluation of blood supply and metabolism in tumor, axillary lymph node and normal breast tissue with F-18 FDG PET/CT in breast cancer: comparison with pathological prognostic factors.
Abdulrezzak U; Akgun H; Tutus A; Kula M; Dogan S; Oz AB; Ok E
BMC Womens Health; 2024 Jan; 24(1):45. PubMed ID: 38229093
[TBL] [Abstract][Full Text] [Related]
2. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
4. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
Orsaria P; Chiaravalloti A; Caredda E; Marchese PV; Titka B; Anemona L; Portarena I; Schillaci O; Petrella G; Palombi L; Buonomo OC
Anticancer Res; 2018 Dec; 38(12):6639-6652. PubMed ID: 30504372
[TBL] [Abstract][Full Text] [Related]
6. Increased FDG uptake in breast cancer is associated with prognostic factors.
Sanli Y; Kuyumcu S; Ozkan ZG; Işik G; Karanlik H; Guzelbey B; Turkmen C; Ozel S; Yavuz E; Mudun A
Ann Nucl Med; 2012 May; 26(4):345-50. PubMed ID: 22359222
[TBL] [Abstract][Full Text] [Related]
7. Metabolic activity of breast cancer metastatic lesions on positron emission tomography/computed tomography: comparison with histological and biological characteristics of primary tumor.
Sobic Saranovic D; Stojiljkovic M; Susnjar S; Odalovic S; Artiko V; Pavlovic S; Grozdic-Milojevic I; Obradovic V
Neoplasma; 2016; 63(2):313-21. PubMed ID: 26774154
[TBL] [Abstract][Full Text] [Related]
8.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
9. Association of
Önner H; Coskun N; Erol M; Eren Karanis Mİ
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(1):11-16. PubMed ID: 34991831
[TBL] [Abstract][Full Text] [Related]
10. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
11. Discordant results in
Parisse-Di Martino S; Faure C; Mognetti T
Cancer Treat Res Commun; 2021; 27():100344. PubMed ID: 33636590
[TBL] [Abstract][Full Text] [Related]
12. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
[TBL] [Abstract][Full Text] [Related]
13. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer.
Kitajima K; Fukushima K; Miyoshi Y; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Maruyama K; Yamano T; Doi H; Yamakado K; Hirota S; Hirota S
Jpn J Radiol; 2016 Mar; 34(3):220-8. PubMed ID: 26715510
[TBL] [Abstract][Full Text] [Related]
15. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma.
Kitajima K; Yamano T; Fukushima K; Miyoshi Y; Hirota S; Kawanaka Y; Miya M; Doi H; Yamakado K; Hirota S
Eur J Radiol; 2016 May; 85(5):943-9. PubMed ID: 27130054
[TBL] [Abstract][Full Text] [Related]
18. Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET/CT.
Jeong YJ; Jung JW; Cho YY; Park SH; Oh HK; Kang S
Nucl Med Rev Cent East Eur; 2017; 20(1):32-38. PubMed ID: 28198519
[TBL] [Abstract][Full Text] [Related]
19. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
[TBL] [Abstract][Full Text] [Related]
20. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
